biologic therapy Archives - Page 2 of 2

FDA Approves Myrbetriq to Treat Pediatric NDO

03/04/2021 adverse effe, angioneurotic edema, antigens, biologic therapy, bladder infection, Child, childhood, children, FDA, headache, hypertension, increased blood pressure, kids, oab (overactive bladder), overactive bladder (oab), pediatrics, Spinal cord injury, u.s. food and drug administration, united states food and drug administration, urinary frequency, Urinary Tract Infection, urinary tract infection (uti), UTI

The US Food and Drug Administration (FDA) has expanded the indication for Mirabegron (Myrbetriq/Myrbetriq Granules) to treat neurogenic detrusor overactivity

Health News

Diabetes Prevention Moves Towards Reality as Studies Published

17/03/2021 biologic therapy, Cetuximab, Diabetes Mellitus, diabetes mellitus type 1, diabetes mellitus type i, endocrine system, endocrinology, Monoclonal Antibody, Rituximab, Type 1 Diabetes

Two newly published studies highlight recent success toward delaying the onset of type 1 diabetes in people at high risk

Health News

US 2019 Suicide Rate Drops, but Will Decline Last?

08/03/2021 2019 Novel Coronavirus, 2019-nCoV, biologic therapy, coronavirus, Depression, Disaster, disaster medicine, Florida, Hawaii:, HCoV-229E, HCoV-OC43, Human coronavirus 229E, Human coronavirus HKU1, Human coronavirus OC43, Idaho, Indiana, injury prevention, Kentucky, Massachusetts, Minnesota, Nebraska, pandemic, social determinants of health, social issues, suicide, urban he, vital statistics, wuhan coronavirus, Wyoming

In 2019, the U.S. suicide rate dropped for the first time in 14 years, driven largely by a significant decline

Online

how to buy lamictal pharm support group without prescription

08/03/2021 acetylsalicylic acid, Allergy, aspirin, Asthma, asthmatic, biologic therapy, biologics, Cetuximab, ent specialty, head and neck surgery; ENT speciality, Monoclonal Antibody, nasal polyp, otolaryngology, polyp of the nose, Rituximab

NEW YORK (Reuters Health) – Dupilumab, a monoclonal antibody targeting interleukin-4 (IL-4) receptor alpha, should be considered in patients with

Health News

No Benefit Seen With Everolimus in Early Breast Cancer

08/03/2021 biologic therapy, breast, Breast cancer, cancer, carcinoma, chemotherapy, endocrine therapy, HER2 negative breast cancer, HER2- breast cancer, Hormone Therapy, inhibitor (mammalian target of rapamycin), malignant breast neoplasm, malignant neoplasia, mammalian target of rapamycin inhibitor, mtor inhibitor, selective estrogen receptor modulator (serm), tamoxifen, target-of-rap, targeted therapy, tor inhibitor

Adding everolimus to adjuvant hormone therapy for early ER+, HER2- breast cancer does not offer any benefit over hormone therapy

Health News

Peanut Sublingual Immunotherapy Feasible and Effective in Toddlers

28/02/2021 adverse effects, allergens, Allergy, allergy to peanuts, Asthma, asthmatic, biologic therapy, chil, Child, childhood, children, clinical research, clinical studies, clinical trials, FDA, Food Allergy, immunotherapy, itch, kids, patient safety, peanut allergy, peanut anaphylaxis, pediatrics, pruritis, pruritus, side effects, tolerance, u.s. food and drug administration, united states food and drug administration

Sublingual immunotherapy for the treatment of peanut allergy is safe and effective, even in children as young as age 1

Health News

Bladder Cancer Indication Withdrawn for Durvalumab

23/02/2021 biologic therapy, bladder, Bladder Cancer, cancer, carcinoma, chemotherapy, clinical research, clinical studies, clinical trials, FDA, grant, immunotherapy, malignant bladder neoplasm, malignant neoplasia, neoadjuvant, u.s. food and drug administration, united states food and drug administration

After failing to improve overall survival in unresectable metastatic bladder cancer in a phase 3 trial, this indication will be